Chimerix

News Releases

2009

Chimerix Raises $16.1 Million in Series E Financing

   

RESEARCH TRIANGLE PARK, NC, August 11, 2009 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, today announced the completion of a $16.1 million Series E financing.  Leading life science venture capital investors Canaan… > Read More

Chimerix, Inc., Appoints Kenneth I. Moch Chief Operating Officer

   

RESEARCH TRIANGLE PARK, NC, July 16, 2009 – Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Kenneth I. Moch has joined the company as Chief Operating Officer.

Mr. Moch brings more than 25 years of experience… > Read More

Chimerix Joins International Network of Organizations to Cure Malaria

   

RESEARCH TRIANGLE PARK, NC, April 2, 2009 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the Company has joined the Medicines for Malaria Venture (MMV) and its network of public-private partnerships… > Read More

2008

Chimerix Completes Phase I Study And Initiates A Phase II Multi-Dose Clinical Trial For CMX001

   

- CMX001 is an Orally Available Broad Spectrum Antiviral Being Investigated for the Treatment of dsDNA Viruses Including Smallpox, BK Virus, CMV and Adenovirus -

RESEARCH TRIANGLE PARK, NC, January 6, 2008 – Chimerix, Inc., a biotechnology company… > Read More

Chimerix Appoints Neil Frazer, M.B., FRCA, FFPM as Chief Medical Officer

   

RESEARCH TRIANGLE PARK, NC - January 3, 2008 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Neil Frazer, M.B., Ch.B., FRCA, FFPM  has joined the company as Chief Medical Officer.

Prior… > Read More

2007

Chimerix Initiates A Multi-Dose Clinical Trial Of The Company’s Lead Compound, CMX001, For The Treatment For Smallpox Infection

   

RESEARCH TRIANGLE PARK, NC, December 11, 2007 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the Company has initiated a multi-dose trial with its lead drug candidate, CMX001, an oral treatment for… > Read More

Merial To Screen Chimerix' Chemical Library For Animal Health Drug Leads

   

DULUTH, GA, and RESEARCH TRIANGLE PARK, NC, January 29, 2007 - Merial Limited and Chimerix, Inc. announced today that they have signed an agreement under which Merial will screen a Chimerix chemical library for animal health drug leads. Under the terms of this agreement,… > Read More

2006

Chimerix Announced Initiation of Phase I clinical trials of CMX001, An Oral Treatment for Smallpox Infection

   

RESEARCH TRIANGLE PARK, NC, June 28 2006 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that it has received U.S. Food and Drug Administration clearance for its Investigational New Drug… > Read More

Chimerix Acquires Lead Compound Library of Antiviral Agents from University of Michigan

   

RESEARCH TRIANGLE PARK, NC, May 24 2006 - Chimerix, Inc., an emerging biotechnology company developing orally available antiviral therapeutics, announced today that it has acquired Dr. Leroy Townsend’s lifetime library of chemical lead compounds from the University… > Read More

Chimerix and USAMRIID Collaborate to Complete Preclinical Development of Smallpox Therapeutic

   

RESEARCH TRIANGLE PARK, NC, April 18, 2006 - Chimerix, Inc., a biotechnology company developing orally available, targeted medicines to treat smallpox and other viral infections, announced today that it has signed a Cooperative Research and Development Agreement (CRADA)… > Read More

 <  1 2 3 >